glp-1 intestinal paralysis lawsuit in kentucky Weight Loss Drugs Ozempic Lawsuit | Stomach Paralysis

Recent developments underscore the relevance of GLP-1R agonists in addressing the complex interplay of cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH)

Compelling CVOT data: Ultimately, health systems attribute value to cardiovascular outcomes, not weight loss on its own

Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today.

/PRNewswire/ -- Daewoong Pharmaceutical (CEOs Seng-Ho Jeon and Chang-Jae Lee) announced on the 6th that it will commence full-scale development of an obesity...